Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: inhalation

Currently viewing:

Administrative data

short-term repeated dose toxicity: inhalation
Type of information:
experimental study
Adequacy of study:
other information
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: see 'Remark'
basic data given, peer reviewed, documentation incomplete (method, clinical observations, hematology results, histopathology results described) Although the study documentation is incomplete, the results described are nevertheless reliable, as the data were produced and published by recognized institutions. Furthermore the results are plausible and in line with all other evidence regarding the chemical and biological properties, i.e. corrosivity, of sulfuryl chloride and its hydrolysis products hydrochloric acid, sulfuric acid, and chlorosulfonic acid.

Data source

Referenceopen allclose all

Reference Type:
Acute and subacute inhalation toxicity of sulfuryl chloride in rats.
Kelly, D.P. and Stula, E.F.
Bibliographic source:
The Toxicologist Vol.3, No. 1, p.62
Reference Type:
secondary source
Sulfuryl chloride, CAS N° 7791-25-5, SIDS Initial Assessment Report
Bibliographic source:
UNEP publications

Materials and methods

Principles of method if other than guideline:
Method: other: no data
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
Sulphuryl dichloride
EC Number:
EC Name:
Sulphuryl dichloride
Cas Number:
Molecular formula:
sulfuroyl dichloride
Details on test material:
- Name of test material (as cited in study report): Sulfuryl chloride as vapor
Purity: approx. 100 % (specially distilled batch)

Test animals


Administration / exposure

Route of administration:
Duration of treatment / exposure:
2 weeks
Frequency of treatment:
6 hours/day and 5 days/week
Doses / concentrations
Doses / Concentrations:
0, 3, 10 or 30 [20] pmm (0, 17, 55, or 166 [110] mg/m3)(measured: 0,0; 3,1; 9,8; 22,3 ppm)

Control animals:
Details on study design:
Post-exposure period: up to 2 weeks

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
effects observed, treatment-related
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
no effects observed
Details on results:
CLINICAL SIGNS AND MORTALITY: The highest exposure concentration (30 ppm) was reduced to 20 ppm after 2 exposures due to excessive weight loss and terminated after 8 exposures due to the death of 2 rats. No mortalities in other exposure groups.
Clinical signs: labored breathing, red discharge from nose, swollen nose, reduced body temperature

BODY WEIGHT AND WEIGHT GAIN: excessive weight loss after 30 ppm, reduced body weight at low and mid dose levels; normal weight gain during reovery

HAEMATOLOGY: Immediately after exposure there was a dose-dependent increase in blood RBC's, hematocrit, and haemoglobin levels in the mid and high dose groups; WBC and neutrophils increased after the high dose

CLINICAL CHEMISTRY: increased blood urea nitrogen in all treated groups; increased chloesterol in mid and high dose groups

ORGAN WEIGHTS: Immediately after exposure there was a dose-dependent increase in lung-to-body weight ratio in the mid and high dose groups.

GROSS PATHOLOGY: lungs not collapsed in mid and high dose animals

HISTOPATHOLOGY: NON-NEOPLASTIC: Mid and high dosed rats showed a fibrino-necrotic bronchopneumonia; in addition, the high-level rats showed a fibrino-purulent rhinitis. lympgoid atrophy in thymus, In the 3 ppm group the only effects were an apparent exacerbation of naturally occurring murine pneumonitis.

OTHER FINDINGS: There was marked recovery from these lesions and a return to normal weight-gains two weeks later. There was a decrease of monocytes in all treated groups at the end of the recovery period.

Effect levels

Dose descriptor:
Effect level:
17 mg/m³ air

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

There was marked recovery from these lesions and a return to normal weight-gains two weeks later. There was a decrease of monocytes in all  treated groups at the end of the recovery period.

Statistical results: no data

Applicant's summary and conclusion